UPDATE 1-FDA panel votes for more data before approval of AstraZeneca drug

June 25, 2014 7:38 PM

12 0

WASHINGTON, June 25 (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.

The panel voted 11-2 that the company should complete a second trial to confirm results seen in a smaller study which, while positive, were not robust enough to convince the committee that they could be reproduced.

Also read: Deutsche Bank Gets a Much-Needed Boost Working for Big Tobacco

Read more

To category page